Advances in the clinical management of inhibitors in hemophilia A and B

Seminars in Hematology

Volumn 53, Issue 1, 2016, Pages 20-27

  Leissinger, Cindy A ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute bleeding; Bypassing therapy; Hemophilia; Immune tolerance induction; Inhibitors; Prophylaxis

Indexed keywords

ACE 910; ACTIVATED PROTHROMBIN COMPLEX; ALN AT3; AMINOCAPROIC ACID; ANTITHROMBIN; BISPECIFIC ANTIBODY; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 ANTIBODY; CONCIZUMAB; CYCLOPHOSPHAMIDE; GENE THERAPY AGENT; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; MC 710; NEUTRALIZING ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RITUXIMAB; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIBODY TITER; BLEEDING; DRUG DOSE REDUCTION; GENE MUTATION; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNE TOLERANCE INDUCTION; IMMUNOADSORPTION; IMMUNOGENICITY; IMMUNOLOGICAL PROCEDURES; IMMUNOSUPPRESSIVE TREATMENT; JOINT DESTRUCTION; MONOTHERAPY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNAI THERAPEUTICS; SINGLE DRUG DOSE; ACUTE DISEASE; ANIMAL; COMPLICATION; HEMORRHAGE; HEMOSTASIS; IMMUNOLOGICAL TOLERANCE;

ACUTE DISEASE; ANIMALS; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGE; HEMOSTASIS; HUMANS; IMMUNE TOLERANCE;

EID: 84957582883     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2015.10.008     Document Type: Review

References (109)

1. Kasper CK. Diagnosis and management of inhibitors to factors VIII and IX. An introductory discussion for physicians. Treatment of Hemophilia Monograph Series, no. 34; September 2004. Available at:. http://www1.wfh.org/publication/files/pdf-1178.pdf.
2. Christophe O.D., Lenting P.J., Cherel G., et al. Functional mapping of anti-factor IX inhibitors developed in patients with severe hemophilia B. Blood 2001, 98(5):1416-1423.
3. Brackmann H.H., Wallny T. Immune tolerance: high-dose regimen. Inhibitors in patients with hemophilia 2002, 45-48. Blackwell Science, Oxford, England. E.C. Rodriguez-Merchan, C.A. Lee (Eds.).
4. DiMichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia 2002, 8(3):280-287.
5. Gouw S.C., van der Bom J.G., Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007, 109(11):4648-4654.
6. Kessler C.M. New perspectives in hemophilia treatment. Am Soc Hematol Educ Program 2005, 429-435.
7. Leissinger C.A. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 2004, 77(2):187-193.
8. Quintana-Molina M., Martinez-Bahamonde F., Gonzalez-Garcia E., et al. Surgery in haemophilic patients with inhibitor: 20 years of experience. Haemophilia 2004, 10(Suppl 2):30-40.
9. Rodriguez-Merchan E.C. Surgery in haemophilic patients with inhibitors. Haemophilia 2004, 10(Suppl 2):1-2.
10. Scalone L., Mantovani L.G., Mannucci P.M., Gringeri A. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006, 12(2):154-162.
11. Walsh C.E., Soucie J.M., Miller C.H. Impact of inhibitors on hemophilia A mortality in the United States. Am J Hematol 2015, 90(5):400-405.
12. Oldenburg J., Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006, 12(Suppl 6):15-22.
13. Astermark J., Berntorp E., White G.C., Kroner B.L. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001, 7(3):267-272.
14. Gill J.C. The role of genetics in inhibitor formation. Thromb Haemost 1999, 82(2):500-504.
15. Lusher J., Abildgaard C., Arkin S., et al. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation. J Thromb Haemost 2004, 2(4):574-583.
16. Aledort L.M., DiMichele D.M. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia 1998, 4(1):68.
17. SIPPET Project. Survey of inhibitors in plasma-product exposed toddlers. Available at:. http://www.sippet.org/Source/SippetStudy.aspx.
18. Verbruggen B., Novakova I., Wessels H., Boezeman J., van den Berg M., Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995, 73(2):247-251.
19. Key N.S. Inhibitors in congenital coagulation disorders. Br J Haematol 2004, 127(4):379-391.
20. White G.C., Rosendaal F., Aledort L.M., Lusher J.M., Rothschild C., Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001, 85(3):560.
21. ®: mode of action. Haemophilia 2004, 10(Suppl 2):3-9.
22. Varadi K., Negrier C., Berntorp E., et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003, 1(11):2374-2380.
23. Hoffman M., Monroe D.M., Roberts H.R. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998, 9(Suppl 1):S61-S65.
24. Villar A., Aronis S., Morfini M., et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 2004, 10(4):352-359.
25. Hilgartner M., Aledort L., Andes A., Gill J. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion 1990, 30(7):626-630. FEIBA Study Group.
26. Abshire T., Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004, 2(6):899-909.
27. Astermark J., Donfield S.M., DiMichele D.M., et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007, 109(2):546-551.
28. Schneiderman J., Rubin E., Nugent D.J., Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007, 13(3):244-248.
29. Negrier C., Goudemand J., Sultan Y., Bertrand M., Rothschild C., Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997, 77(6):1113-1119.
30. Brummel-Ziedins K.E., Branda R.F., Butenas S., Mann K.G. Discordant fibrin formation in hemophilia. J Thromb Haemost 2009, 7(5):825-832.
31. Healey J.F., Lubin I.M., Lollar P. The cDNA and derived amino acid sequence of porcine factor VIII. Blood 1996, 88(11):4209-4214.
32. Hay C.R., Lozier J.N., Lee C.A., et al. Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey. Thromb Haemost 1996, 75(1):25-29.
33. Kruse-Jarres R., St-Louis J., Greist A., et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia 2015, 21(2):162-170.
34. Kempton C.L., Abshire T.C., Deveras R.A., et al. Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. Haemophilia 2012, 18(5):798-804.
35. Chowdary P., Lethagen S., Friedrich U., et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost 2015, 13(5):743-754.
36. Mant T., Akinc A., Simon A.R., et al. A subcutaneously administered RNAi therapeutic (ALN-AT3) targeting antithrombin for treatment of hemophilia: interim phase 1 study results in healthy volunteers and patients with hemophilia A or B. Blood 2014, 124(21). abstract 693.
37. Alnylam Pharmaceuticals. New positive clinical data for ALN-AT#, a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders. Available at:. https://ash.confex.com/ash/2014/webprogram/Paper75077.html.
38. Shima M., Hanabusa H., Taki M., et al. Safety and prophylactic efficacy profiles of ACE910, a humanized bispecific antibody mimicking the FVIII cofactor function, in Japanese hemophilia A patients both without and with FVIII inhibitors: first-in-patient phase 1 study. Blood 2014, 124(21):691.
39. Shirahata A., Fukutake K., Takamatsu J., et al. A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics. Haemophilia 2013, 19(6):853-860.
40. DiMichele D.M., Hoots W.K., Pipe S.W., Rivard G.E., Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Hemophilia 2007, 13(Suppl 1):1-22.
41. Valentino L.A., Kempton C.L., Kruse-Jarres R., et al. US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors. Haemophilia 2015.
42. Ho A.Y., Height S.E., Smith M.P. Immune tolerance therapy for haemophilia. Drugs 2000, 60(3):547-554.
43. Hilgartner M.W., Knatterud G.L. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983, 61(1):36-40.
44. Warrier I., Ewenstein B.M., Koerper M.A., et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J. Pediatr Hematol Oncol. 1997, 19(1):23-27.
45. Ewenstein B.M., Takemoto C., Warrier I., et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 1997, 89(3):1115-1116.
46. DiMichele D.M., Kroner B.L. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002, 87(1):52-57.
47. Brackmann H.H., Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977, 2(8044):933.
48. Mariani G., Ghirardini A., Bellocco R. Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee. Thromb Haemost 1994, 72(1):155-158.
49. Lenk H. The German Registry of immune tolerance treatment in hemophilia-1999 update. Haematologica 2000, 85(10 Suppl):45-47.
50. Haya S., Lopez M.F., Aznar J.A., Batlle J. Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry. Haemophilia 2001, 7(2):154-159.
51. Hay C.R., DiMichele D.M. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012, 119(6):1335-1344.
52. Earnshaw S.R., Graham C.N., McDade C.L., Spears J.B., Kessler C.M. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia 2015, 21(3):310-319.
53. Colowick A.B., Bohn R.L., Avorn J., Ewenstein B.M. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000, 96(5):1698-1702.
54. Ewing N.P., Sanders N.L., Dietrich S.L., Kasper C.K. Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors. JAMA 1988, 259(1):65-68.
55. Freiburghaus C., Berntorp E., Ekman M., Gunnarsson M., Kjellberg B., Nilsson I.M. Tolerance induction using the Malmo treatment model 1982-1995. Haemophilia 1999, 5(1):32-39.
56. Gruppo R.A., Valdez L.P., Stout R.D. Induction of immune tolerance in patients with hemophilia A and inhibitors. Am J Pediatr Hematol Oncol 1992, 14(1):82-87.
57. Mauser-Bunschoten E.P., Nieuwenhuis H.K., Roosendaal G., van den Berg H.M. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995, 86(3):983-988.
58. Ragni M.V., Ojeifo O., Feng J., et al. Risk factors for inhibitor formation in haemophilia: a prevalent case-control study. Haemophilia 2009, 15(5):1074-1082.
59. Coppola A., Margaglione M., Santagostino E., et al. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost 2009, 7(11):1809-1815.
60. Ter Avest P.C., Fischer K., Gouw S.C., Van Dijk K., Mauser-Bunschoten E.P. Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units. Haemophilia 2010, 16(102):71-79.
61. Lapalud P., Rothschild C., Mathieu-Dupas E., et al. Anti-A2 and anti-A1 domain antibodies are potential predictors of immune tolerance induction outcome in children with hemophilia A. J Thromb Haemost 2015, 13(4):540-547.
62. DiMichele D., Rivard G., Hay C., Antunes S. Inhibitors in haemophilia: clinical aspects. Haemophilia 2004, 10(Suppl 4):140-145.
63. Kreuz W., Escuriola-Ettingshausen C., Auerswald G. Immune tolerance induction in haemophilia A patients with inhibitors: the choice of concentrate affecting success. Haematologica 2001, 86(Suppl 4):16-20.
64. Auerswald G., Spranger T., Brackmann H.H. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 2003, 88(6):EREP05.
65. Kreuz W. Epidemiology of inhibitors and current treatment strategies. Haematologica 2003, 88:EREP04.
66. Orsini F., Rothschild C., Beurrier P., Faradji A., Goudemand J., Polack B. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica 2005, 90(9):1288-1290.
67. Gringeri A., Musso R., Bernasconi S. Immunotolerance induction (ITI) with high purity FVIII/VWF concentrates in inhibitor patients with a high risk of a poor response to ITI: a prospective surveillance. J Thromb Haemost 2005, 3(Suppl 1):A207.
68. Behrmann M., Pasi J., Saint-Remy J.M., Kotitschke R., Kloft M. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 2002, 88(2):221-229.
69. Berntorp E. Immune tolerance induction: recombinant vs. human-derived product. Haemophilia 2001, 7(1):109-113.
70. Leissinger C., Josephson C.D., Granger S., et al. Rituximab for treatment of inhibitors in haemophilia A. A phase II study. Thromb Haemost 2014, 112:3.
71. Franchini M., Mengoli C., Lippi G., et al. Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients' analysis. Haemophilia 2008, 14(5):903-912.
72. Collins P.W., Mathias M., Hanley J., et al. Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort. J Thromb Haemost 2009, 7(5):787-794.
73. Srivastava A., Brewer A.K., Mauser-Bunschoten E.P., et al. Guidelines for the management of hemophilia. Haemophilia 2013, 19(1):e1-47.
74. National Hemophilia Foundation. MASAC [Medical and Scientific Advisory Council] Recommendation 179. MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). Adopted November 4, 2007. Available at:. http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007.
75. Aledort L.M., Haschmeyer R.H., Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994, 236(4):391-399.
76. Manco-Johnson M.J., Abshire T.C., Shapiro A.D., et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007, 357(6):535-544.
77. Gringeri A., Lundin B., von Mackensen S., Mantovani L., Mannucci P.M. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011, 9(4):700-710.
78. Valentino L.A., Mamonov V., Hellmann A., et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012, 10(3):359-367.
79. Manco-Johnson M.J., Kempton C.L., Reding M.T., et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost 2013, 11(6):1119-1127.
80. Windyga J., Lissitchkov T., Stasyshyn O., et al. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level
81. Panicker J., Warrier I., Thomas R. Lusher JM. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia 2003, 9(3):272-278.
82. Steen Carlsson K., Hojgard S., Glomstein A., et al. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 2003, 9(5):555-566.
83. Shapiro A.D., Donfield S.M., Lynn H.S., et al. Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study. Pediatrics 2001, 108(6):E105.
84. Leissinger C.A. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. Haemophilia 1999, 5(Suppl 3):25-32.
85. Konkle B.A., Ebbesen L.S., Erhardtsen E., et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007, 5(9):1904-1913.
86. Leissinger C., Gringeri A., Antmen B., et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011, 365(18):1684-1692.
87. Antunes S.V., Tangada S., Stasyshyn O., et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia 2014, 20(1):65-72.
88. Hoots W.K., Ebbesen L.S., Konkle B.A., et al. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 2008, 14(3):466-475.
89. Gringeri A., Leissinger C., Cortesi P.A., et al. Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study. Haemophilia 2013, 19(5):736-743.
90. Stasyshyn O., Antunes S., Mamonov V., et al. Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study. Haemophilia 2014, 20(5):644-650.
91. Leissinger C.A., Singleton T., Kruse-Jarres R. How we use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors. Blood 2015.
92. Inhibitors to factor VIII/IX: treatment of inhibitors-immune tolerance induction. Textbook of hemophilia 2005, 74-79. Hay CRM, Blackwell, Malden, MA. C.A. Lee, E.E. Berntorp, W.K. Hoots (Eds.).
93. Ettingshausen C.E., Kreuz W. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: a prospective clinical case series. Haemophilia 2010, 16(1):90-100.
94. Gouw S.C., van den Berg H.M., Fischer K., et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013, 121(20):4046-4055.
95. Astermark J. Overview of inhibitors. Semin Hematol 2006, 43(Suppl 4):S3-S7.
96. Astermark J., Lacroix-Desmazes S., Reding M.T. Inhibitor development. Haemophilia 2008, 14(Suppl 3):36-42.
97. Astermark J., Oldenburg J., Carlson J., et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006, 108(12):3739-3745.
98. Astermark J., Oldenburg J., Pavlova A., Berntorp E., Lefvert A.K. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006, 107(8):3167-3172.
99. Astermark J., Wang X., Oldenburg J., Berntorp E., Lefvert A.K. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007, 5(2):263-265.
100. Young G., Shafer F.E., Rojas P., Seremetis S. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 μg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008, 14(2):287-294.
101. von Drygalski A., Cramer T.J., Bhat V., Griffin J.H., Gale A.J., Mosnier L.O. Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant. J Thromb Haemost 2014, 12(3):363-372.
102. Milanov P., Ivanciu L., Abriss D., et al. Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice. Blood 2012, 119(2):602-611.
103. Bunce M.W., Toso R., Camire R.M. Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro. Blood 2011, 117(1):290-298.
104. Ivanciu L., Toso R., Margaritis P., et al. A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia. Nat Biotechnol 2011, 29(11):1028-1033.
105. Dockal M., Hartmann R., Fries M., et al. Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI). J Biol Chem 2014, 289(3):1732-1741.
106. Sehgal A., Barros S., Ivanciu L., et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med 2015, 21(5):492-497.
107. Brackmann H.H., Oldenburg J., Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors-twenty years' 'Bonn protocol'. Vox Sang 1996, 70(Suppl 1):30-35.
108. Rocino A., Papa M.L., Salerno E., Capasso F., Miraglia E., de Biasi R. Immune tolerance induction in haemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institution. Haemophilia 2001, 7(1):33-38.
109. Smith M.P., Spence K.J., Waters E.L., et al. Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution. Thromb Haemost 1999, 81(1):35-38.